Antibiotic therapy of severe community-acquired pneumonia

Combined antibiotic therapy, including the use of intravenous cefotaxime (a beta-lactam) and azithromycin (a macrolide) was shown advantageous from both clinical and economic viewpoints in the treatment of severe community-acquired pneumonia.

Saved in:
Bibliographic Details
Published inAntibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] Vol. 54; no. 3-4; p. 29
Main Authors Molchanova, O V, Suleĭmanov, S Sh, Ostrovskiĭ, A B
Format Journal Article
LanguageRussian
Published Russia (Federation) 2009
Subjects
Aged
Anti-Bacterial Agents - economics
Anti-Bacterial Agents - therapeutic use
Azithromycin - economics
Azithromycin - therapeutic use
Cefotaxime - economics
Cefotaxime - therapeutic use
Community-Acquired Infections - drug therapy
Community-Acquired Infections - economics
Costs and Cost Analysis
Drug Therapy, Combination
Female
Humans
Injections, Intravenous
Length of Stay - economics
Male
Medical Records
Middle Aged
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:Combined antibiotic therapy, including the use of intravenous cefotaxime (a beta-lactam) and azithromycin (a macrolide) was shown advantageous from both clinical and economic viewpoints in the treatment of severe community-acquired pneumonia.
ISSN:0235-2990